

RESEARCH

Open Access



Intranasal SARS-CoV-2 infection changes the transcriptome of the mouse trigeminal ganglion and brainstem: potential mechanisms underlying headache and trigeminal pain presentation in COVID-19

Jian Huang¹, Elodie Reboussin¹, Lola Bianchi², Christelle Enond³, Serban Morosan^{3,4}, Isabelle Malet⁵, Stéphane Fouquet¹, Eugénie Genestant¹, Frédéric Blond¹, William Rostène¹, Christophe Baudouin^{1,6,7}, Stéphane Melik Parsadaniantz¹, Stéphane Marot⁵, Anne-Genevieve Marcelin^{5,8}, Florence Cayetanot², Xavier Guillonéau^{1†}, Laurence Bodineau^{2†}, Laurence Bourgeais-Rambur^{1,9†} and Annabelle Réaux-Le Goazigo^{1*†}

Abstract

Multiple symptoms have been observed in COVID-19 patients, including migraine and facial pain which may result from the sensitization of the trigeminal ganglion (TG) and brainstem. Recent studies suggest that SARS-CoV-2 may invade trigeminal nerve endings in the nasal cavity. However, despite these insights, the precise underlying mechanisms remain poorly understood. Here, we investigated the cellular and molecular changes in the TG and brainstem with a special attention for the spinal trigeminal nucleus in the K18-hACE2 mouse model infected with SARS-CoV-2. We first confirmed the expression of the cellular proteins playing a role in SARS-CoV-2 cell entry (ACE2, TMPRSS2, and NRP1) in both structures. We reported the expression of the viral nucleocapsid (N) and spike (S) proteins in TG and brainstem at 6 days post infection by multimodal approaches (RNAseq, RNAscope, and immunofluorescence). In the TG, S and N proteins were detected in nerve fibers as well as in TRPV1 and CGRP nociceptive neurons. Transcriptomic analyses of the TG from infected K18-hACE2 revealed significant changes in gene expression, including *Ccl2*, *Atf3*, *Cxcl10*, *Saa3*, and *Plin4* genes. Additionally, increased immunoreactivity for ATF3 and Iba1 was detected in the TG of infected mice. In the brainstem, SARS-CoV-2 protein was exclusively found in neurons, with no detection in astrocytes or microglial cells, the latter exhibiting an activated form in SARS-CoV-2 mice. Bulk RNA-Seq analysis revealed a robust inflammatory response characterized by cytokine and

[†]Xavier Guillonéau and Laurence Bodineau contributed equally to this work.

[†]Laurence Bourgeais-Rambur and Annabelle Réaux-Le Goazigo co-supervised this work.

*Correspondence:
Annabelle Réaux-Le Goazigo
annabelle.reaux@inserm.fr

Full list of author information is available at the end of the article



© The Author(s) 2026. **Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by/4.0/>.

chemokine storm, inflammasome activation (*Gsdmd*, *Casp11*, *Casp1*, and *Nlrp3*), markers of neuronal activation (*Jun*, *Fos*, *Fosb*), neuronal injury (*Atf3*), and pain-associated genes (*Tacr1*, *Gfra1*, *Ntrk1*, *Slc17a6*, *Ptgs2*). As found in the TG, we observed that infected neurons were found within a dense network of CGRP nociceptive nerve fibers in the trigeminal brainstem. Finally, we provided gene interaction networks and identified specific SARS-CoV-2 biomarkers *Saa3*, *Cxcl10*, *Ccl2*, *Atf3*, and *Plin4* in TG and brainstem, which could serve as potential indicators of disease severity. In conclusion, this study reports a robust set of transcriptomic and cellular changes triggered by SARS-CoV-2 in the TG and brainstem, offering a potential mechanistic explanation for sensory abnormalities, such as migraine and pain, observed in COVID-19 patients.

Keywords SARS-CoV-2, Trigeminal ganglion, Sensory neurons, Brainstem, Inflammation, Migraine, Pain, Nociceptors, Biomarker

Introduction

Over five years since its emergence in Wuhan, Coronavirus Disease 2019 (COVID-19) has led to over 770 million reported cases globally and the pandemic has resulted in over 6.9 million deaths worldwide (WHO COVID-19 Dashboard, 2023, *World Health Organization*; 2023 Sep 21 [cited 2023 Sep 21]). [Reference Source](#). Neurological symptoms are prevalent in up to 80% of individuals infected with the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus responsible for COVID-19. Among these, headache and trigeminal pain are the most common neurological symptoms in COVID-19 patients [1], suggesting a dysfunction of the trigeminal ganglion (TG) and brainstem, two main structures participating in trigeminal pain [2, 3]. Furthermore, serum alpha-calcitonin gene-related peptide (CGRP) levels are increased in COVID-19 patients with headache indicating an activation of the trigeminal system [4]. However, the underlying cellular and molecular changes in the TG and brainstem remain poorly investigated. SARS-CoV-2 infection in cells (SARS-CoV-2 cellular tropism) is primarily facilitated by the binding of its spike (S) to the cell surface receptor angiotensin-converting enzyme 2 (ACE2). This process is further enhanced by transmembrane protease, serine 2 (TMPRSS2), which primes the S protein for fusion with the host cell membrane [5]. Additionally, the transmembrane glycoprotein neuropilin-1 (NRP1) has recently been implicated as a cofactor that may also assist in viral entry [6]. In addition, the nucleocapsid (N) protein, a core component of the SARS-CoV-2 virus, plays pivotal roles in inflammation, cell death, innate antiviral immunity, and adaptive antiviral immunity [7]. Many studies have revealed a subset of tissues and cell types that are potentially susceptible to SARS-CoV-2 using single-cell RNA-seq (scRNA-seq) and immunocytochemistry for profiling the co-expression of ACE2 and TMPRSS2 across healthy human tissues [8], however their specific expression and localization in the TG and brainstem, which are known to play key roles in migraine pathophysiology [9], have not been studied. These areas are critical for understanding the potential

neurological impacts of SARS-CoV-2, including its involvement in trigeminal pain development.

Among the various transgenic models, K18-hACE2 mice (B6.Cg-Tg(K18-ACE2)2Prlmn/J), which express human ACE2 under the control of the cytokeratin-18 promoter, have become a widely used model for studying SARS-CoV-2 infection [10–12]. Studies have shown that in this mouse model, the brain emerges as a primary target for viral replication [13]. The K18-hACE2 mouse model has thus become an invaluable tool for studying not only the systemic spread of SARS-CoV-2 but also the molecular and cellular mechanisms underlying its neuroinvasive potential and the associated neurological manifestations. However, the precise pathophysiological mechanisms by which SARS-CoV-2 infection leads to trigeminal pain manifestations, such as headache and migraine, remain incompletely understood. Meinhardt et al. [14] reported the presence of SARS-CoV-2 viral RNA within the human TG. Supporting this, a study using hACE2 transgenic mice has demonstrated the presence of both viral genomes and infectious virions in the trigeminal nerve, which could serve as a potential route of neuroinvasion and a contributor to COVID-19-associated orofacial pain [15].

Although accumulating evidence suggests the trigeminal pathway as a potential route for SARS-CoV-2 neuroinvasion, the precise expression patterns of key viral entry factors (ACE2, TMPRSS2, and NRP1) within the TG and brainstem, particularly the spinal trigeminal nucleus, remain poorly characterized.

Furthermore, the transcriptomic alterations induced by SARS-CoV-2 infection in these regions have yet to be comprehensively characterized. Importantly, the precise localization of viral components within nociceptive neurons, which are central to trigeminal pain signaling and migraine pathophysiology, remains largely unexplored.

This study aims to provide a comprehensive analysis of the cellular and molecular responses of the TG and the spinal trigeminal nucleus in the brainstem to intranasal infection with SARS-CoV-2 Wuhan/WA1/2020 strain in K18-hACE2 male mice. We evaluated the expression of key viral entry factors (ACE2, TMPRSS2, and NRP1)

in both the TG and brainstem and characterized the infection-induced transcriptomic and cellular changes in both structures. Additionally, we identified SARS-CoV-2 within nociceptive neurons expressing transient receptor potential vanilloid 1 (TRPV1) and calcitonin gene-related peptide (CGRP) in the TG and observed that infected neurons in the spinal trigeminal nucleus are in close proximity to CGRP-positive nociceptive fibers. Finally, we found that the expression of inflammation- and injury-associated genes (*Saa3*, *Cxcl10*, *Ccl2*, *Plin4* and *Atf3*) increased in parallel with Spike expression, suggesting that these genes may represent biomarkers of SARS-CoV-2 severity, as reflected by viral load.

In conclusion, these findings advance our understanding of SARS-CoV-2 neurotropism within the trigeminal pathway and provide mechanistic insights into the molecular basis of orofacial pain, such as migraine, frequently reported in COVID-19 patients.

Materials and methods

The French translation of the Directive 2010/63/UE (decree n° 2013–118 from February 1, 2013, its 3 arrests from April 1, 2013) requires that investigators obtain from the authority (Research Ministry) a project license on the concerned species for a defined type of experiments and that animals are housed and experiments performed in an accredited facility. The UMS28 accreditation number is D75-13-08 and was delivered by Agricultural Ministry - Animal Welfare Services - for the rodent husbandry, surgery and veterinary laboratory. Every animal experiment is performed only after an ethical evaluation and only if no alternatives (3Rs) are available. Protocols were approved by Charles Darwin Ethics Committee for Animal Experimentation (Ce5/2011/05; APAFIS#25473-2020051817434364 v4).

K18h-ACE2 mice

Male hemizygous transgenic mice expressing human *ACE2* under the K18 promoter (B6.Cg-Tg(K18-*ACE2*)2Prln/J (K18-hACE2) were purchased from Jackson Laboratories via Charles River Laboratories (L'Arbresle, France), bred and maintained at Sorbonne University animal facilities (UMS28 Phenotyping small animal). The mice were randomly assigned to cages, with a maximum of five mice. Mice were fed A04 SP-10 irradiated diet (SAFE Diets, Augy, France) and provided autoclaved water in bottle *ad libitum*. Randomization and blinding were not possible due to pre-defined housing conditions (separated isolators between infected and non-infected animals).

SARS-CoV-2 production

The SARS-CoV-2 strain (GenBank MW322968) was isolated from a patient with COVID-19 hospitalized at the

Pitié-Salpêtrière University Hospital. The patient's infection was confirmed by a positive RT-PCR test for SARS-CoV-2 on March 6, 2020, and the virus was isolated by inoculating Vero cells with a sputum sample in our animal biosafety level-3 (ABSL-3) facility. Viral stocks were generated from a passage of the isolate on Vero cells. The supernatants were harvested on day 4, filtered, ultracentrifuged, and resuspended in HNE buffer. Viral stock titration was performed on Vero E6 using the limiting dilution assay, allowing calculation of the 50% infectious dose in tissue culture (TCID₅₀).

Mice intranasal infections

Viral infection was performed in an ABSL-3 facility (UMS28 Phenotyping small animal). Under xylazine/ketamine anesthesia (xylazine 10 mg/kg, ketamine 100 mg/kg; 0.1 ml/10 g), male K18-hACE2 mice (11–22-weeks; $n=25$) were infected with 2.4×10^4 plaque-forming units (PFU) of SARS-CoV2 by intranasal inoculation (12–17 μ l). K18-hACE2 mice ($n=18$) intranasally inoculated with an equal volume of HNE buffer were used as a mock-infection control. The mice were weighed every day.

Tissues sampling

Fresh tissues for RNA seq analysis

Mice were deeply anesthetized and euthanized using an overdose of ketamine (100 mg/kg) and xylazine (10 mg/kg) administered intraperitoneally. TG and brainstem were then dissected on ice from infected ($n=12$) and mock ($n=6$) mice. Each brainstem sample was collected on ice by an experienced experimenter using neuroanatomical and vascular landmarks. The caudal end of the sample was defined at the transition between medulla oblongata and the first cervical segment of the spinal cord (bregma – 8.15 mm). This level corresponds to the level where vertebral arteries reach the lateral edge of the sample, which corresponded to the appearance of medullary pyramids on either side of the midline on the ventral surface of the medulla oblongata. The rostral edge was defined at the transition between the mesencephalon and the diencephalon (bregma – 3.15 mm), corresponding dorsally to the rostral edge of the superior colliculi and ventrally to the rostral edge of the cerebral peduncles. Following isolation of the brainstem, the cerebellum was carefully microdissected and excluded from the samples. Tissues were either immediately immersed in RNAlater (Fischer Scientific) and stored at -80°C until use or directly stored at -80°C until use.

Fixed tissues for immunohistochemistry and RNAscope analysis

SARS-CoV-2-infected ($n=9$) and uninfected ($n=4$) mice were anesthetized (xylazine 10 mg/kg-ketamine 100 mg/kg)

kg; 0.1 ml/10 g, i.p.) and a transcardiac perfusion of cold physiological saline followed by a solution of 4% paraformaldehyde (PFA, in 0.1 M phosphate buffer pH 7.4) was quickly performed. After fixation, lungs, TG, and brainstem were dissected and then postfixed by immersion in 4% PFA for 24–48 h at 4 °C. Tissues were cryoprotected for 48 h in 0.1 M phosphate buffer containing 30% sucrose before being sectioned in a cryostat (Leica CM3050 S). TG and lungs were sectioned at 14 µm and mounted on SuperFrost™ slides (Eppredia), then stored at –20 °C. Brainstems were sectioned at 50 µm and free-floated in 0.1 M phosphate buffer solution (PBS), then stored at +4 °C.

RNA extraction and RNA-Seq analysis

Total RNA was extracted from TG and brainstem using the RNeasy mini kit (Qiagen, Germany) or Nucleospin RNA II kit (Macherey-Nagel, Düren, Germany, Cat. #740955) according to the manufacturer's protocol. RNA quality and quantity were evaluated using BioAnalyzer 2100 (Agilent Technologies, Santa Clara, CA, USA) with the RNA 6000 Nano Kit (Agilent Technologies, Cat. #5067–1511). RNA sequencing libraries were constructed from 250 ng of total RNA using a modified TruSeq RNA Sample preparation kit protocol. Fastq files obtained from the sequencing facility were processed by the cellular and tissue phenotyping platform at the Vision Institute. Briefly, they were aligned using STAR (v2.7.9a) against the mouse genome (Ensembl version 106) supplemented with a copy of the human ACE2 transgene, using the “--quantMode GeneCounts” to extract the raw counts for each gene. Alignments were performed under stringent parameters, discarding reads with an alignment score below 66% and removing all non-uniquely mapped reads to ensure unambiguous assignment of mACE2 and mouse gene expression. Raw count files were next concatenated into a single file for downstream analyses.

A sample file was created with the sample data. The count file and the sample file were loaded in our in-house R Shiny application EYE DV seq. We added 1 to all counts in the count file to avoid any 0 read count errors. We then removed the genes having a total count of less than 10 across all samples. Finally, the DESeq2 (v1.40.2) analysis was performed comparing the groups defined in the ‘condition’ column, with ‘control’ as control group and ‘condition’ as condition. The results were then filtered for significant genes using the p-values adjusted with the FDR procedure (<0.05). An enrichment analysis was performed to study the implicated pathways, using the Reactome database (using the Bioconductor package ‘ReactomePA’ (v1.44.0) and the GO database (using the Bioconductor packages ‘org.Mm.eg.db’ (v 3.10.0) and ‘clusterProfiler’ (v 4.8.1)).

For SARS-CoV-2 RNA detection, the RNA-seq FASTQ files were aligned to SARS-CoV-2 genome, and the corresponding transcripts were normalized using DESeq2 and displayed in a heatmap using the R package ComplexHeatmap. Using the clusterProfiler package, we performed an Over-Representation Analysis (ORA) to identify enriched functional terms among differentially expressed genes in the TG and brainstem. ORA is a functional enrichment method used to determine whether specific biological categories (e.g., GO terms) are statistically overrepresented in a gene list of interest, compared to what would be expected by chance. This analysis was conducted using the enrichGO function from clusterProfiler (v4.14.6) in RStudio (4.4). The Bioconductor annotation package org.Mm.eg.db (v3.20) was used for genome-wide annotation and gene identifier mapping in *Mus musculus*.

The analysis was restricted to GO Biological Process terms, with a p-value cutoff of 0.05 and Benjamini–Hochberg correction for multiple testing. The TG and brainstem transcriptomic data were submitted to the Gene Expression Omnibus (GEO) repository and assigned GEO accession number GSE308948.

scRNA-seq database analysis in mouse TG

We used the snRNA-seq database (<https://painseq.shinyapps.io/tg-painseq/>), which contains gene expression data from 108,375 mouse TG nuclei [16]. The neuronal and non-neuronal cell subpopulations in this atlas were annotated based on the pioneering work of Klein et al. (2015), which employed droplet barcoding for single-cell transcriptomics. We used this atlas to evaluate the expression of *Calca* (encoding CGRP), *Nrp1*, and *Trpv1* by the different subpopulations of mouse TG cells.

Immunohistochemistry on lung, TG, and brainstem

Frozen TG and lung sections were washed in 0.1 M PBS and incubated in blocking solution (5% normal donkey serum and 0.1% Triton X-100) for 2 h at room temperature. Then, sections were incubated with primary antibody solution overnight at 4 °C. Free-floating brainstem sections were blocked for 1 h in blocking solution (5% normal donkey serum, 2.5% bovine serum albumin, and 0.3% Triton X-100) and incubated in primary antibody solution for 3 days at 4 °C. After washing in 0.1 M PBS, sections were incubated with secondary antibody solution and DAPI solution (dilution 1:2000). After washing in 0.1 M PBS, sections were mounted with fluorescence mounting medium and coverslips. Primary antibodies used in this study were rabbit anti-Iba1 (Wako, Cat. #019-19741, 1:500), mouse anti-β-Tubulin-III (Abcam, ab78078, 1:500), rabbit anti-Nucleocapsid (Euromedex, GTX135357-S, 1:500), mouse anti-Spike (Euromedex,

GTX632604, 1:500), mouse anti-NeuN (Sigma-Aldrich, MAB377, 1:500), rabbit anti-ATF3 (Santa Cruz Biotechnology, sc-22798, 1:500), mouse anti-GFAP (1:500; MilliporeSigma G3893), and goat anti-CGRP (1:300; Abcam ab36001). Secondary antibodies used were Alexa Fluor™ 488 donkey anti-rabbit (Invitrogen, Cat. #A-21206, 1:500), Alexa Fluor™ 594 donkey anti-rabbit (Invitrogen, Cat. #A-21207, 1:500), Alexa Fluor™ 488 donkey anti-mouse (Invitrogen, Cat. #A-21202, 1:500), Alexa Fluor™ 488 donkey anti-mouse antibody (Invitrogen, Cat. #A-21203, 1:500), and Alexa Fluor 488 donkey anti-goat (1:500; Invitrogen Cat. #A-11055). Control sections were processed in parallel, but with the omission of primary or secondary antibodies. No labeling was observed in such conditions (not shown). Sections were mounted with fluorescence mounting medium and coverslips and imaged as described below.

RNAscope fluorescence in situ hybridization (FISH) in lung and TG

Sections were washed in 0.1 M PBS, then heated for antigen retrieval for 5 min in +100 °C RNAscope™ Target Retrieval Reagents (Advanced Cell Diagnostics, Cat. #322000). Peroxidases and proteins were removed sequentially by RNAscope H₂O₂ and protease reagents (Advanced Cell Diagnostics, PN 322381) before hybridizing the mRNAs in the sections with SARS-CoV-2 probes: RNAscope™ Probe-V-nCoV-orf1ab-O1 (Advanced Cell Diagnostics, Cat. #859981), RNAscope™ Probe-V-nCoV-N (Advanced Cell Diagnostics, Cat. #846081-C2), RNAscope™ Probe-V-nCoV2019-S (Advanced Cell Diagnostics, Cat. #848561-C3), and RNAscope™ Probe-Mm-Trpv1 (Advanced Cell Diagnostics, Cat. #313331). Next, probes were amplified with HRP recombinant molecules by RNAscope™ Multiplex Fluorescent Detection Kit v2 (Advanced Cell Diagnostics, Cat. #323110) before reacting with the following dyes: TSA Vivid™ Fluorophore Kit 520 (Tocris Bioscience, Cat. #7523), TSA Vivid™ Fluorophore Kit 570 (Tocris Bioscience, Cat. #7526), and TSA Vivid™ Fluorophore Kit 650 (Tocris Bioscience, Cat. #7527). Each experiment was validated by using the RNAscope™ 3-plex Positive Control Probe-Mm (Advanced Cell Diagnostics, Cat. #320881) and RNAscope™ Probe Diluent (negative control) (Advanced Cell Diagnostics, Cat. #300041) (not shown). Sections were mounted with fluorescence mounting medium and coverslips and imaged as described below.

Epifluorescence and confocal microscopy image analysis

Tissue sections were imaged using a Zeiss M1 epifluorescence microscope (Carl Zeiss, Axio ImagerM1) or an inverted Olympus Fluoview FV1000 confocal microscope. Confocal Z-stack images were acquired with a 40× oil immersion objective (NA = 1.3). Z-stacks were

captured with a step size of 0.54 µm across the entire thickness of the tissue section. The resulting image stacks were converted to Imaris file format (.ims) using ImarisFileConverter 10.2.0 and imported into Imaris software (Bitplane, version 10.2.0) for three-dimensional reconstruction. Surfaces were then created using the « surface » module, based on intensity thresholds automatically or manually adjusted to define positive signal for the SARS-CoV-2 nucleocapsid protein (green) and CGRP (red). Volume rendering and 3D reconstructions were performed, providing insight into spatial relationships and distribution patterns of both markers within the nucleus of the TG. The movie was realized with the « animation » module in the XZ axis. Image stacks were projected to maximum intensity and exported in TIFF. Images were then transferred to FIJI to do quantification. For the 3D reconstruction of SARS-CoV-2 nucleocapsid with NeuN, GFAP and Iba1 markers, 3D constructions were created from merged z-stacks using Imaris software and were digitally zoomed to best illustrate the relevant spatial features. To generate image mosaics of the TG section, the Multi Area Time lapse (MATL) module of the Fluoview software was used to program a 10% overlap between adjacent tiles. Montage was then processed using Fluoview software or ImageJ stitching plugins [17] or Bitplane Imaris Stitcher 9.3.1. Image processing.

The epifluorescence microscope is equipped with a digital camera (Axio Cam HRC; Carl Zeiss) and image acquisition software (Zen; Carl Zeiss). Tiff images were recorded with acquisition parameters maintained constant for all samples. For the quantification of injured sensory neurons, slides containing 6 sections of TG for each animal were immunostained with ATF3 antibody and visualized at x20 magnification. The number of neurons with cell body nuclei positively stained for ATF3 was quantified in 3 to 4 sections of the whole TG, including the V1, V2 and V3 branches (mock-infected mice: $n=3$; SARS-CoV-2-infected mice: $n=6$). To quantify Iba1 labeling density, slides containing 6 sections of TG for each animal were immunostained with Iba1 antibody and visualized at x40 magnification. Images were processed using the ImageJ Program. Image files were opened in gray-scale. Using the thresholding function to discriminate Iba1 immunoreactivity from the surrounding background, the area fraction covered by Iba1-positive cells (i.e., stained area fraction) above this set threshold was estimated within a standard area. Data from each mouse included 2 to 3 sections of the TG (mock-infected group: $n=4$; SARS-CoV-2-infected group: $n=7$). For each section, two distinct areas were analyzed, and the areas fractions values were averaged to obtain a single stained area fraction value per mouse. The microscopic analysis was performed by an experimenter blinded to the treatment group.




Fig. 1 (See legend on next page.)

(See figure on previous page.)

Fig. 1 Weight loss, lung infection, and inflammation in SARS-CoV-2-infected mice. **A** Experimental workflow. K18-hACE2 transgenic mice were mock-infected or infected with 2.4×10^4 PFU of SARS-CoV-2. **B** Body weight changes for K18-hACE2 transgenic mice SARS-CoV-2-infected ($n=21$) and mock-infected ($n=10$). Error bars represent standard error of the mean (SEM). One-way ANOVA based on a mixed-effects model followed by the two-stage step-up method of Benjamini, Krieger, and Yekutieli's multiple comparison test was used to calculate p values of significance. Statistical significance was defined as $p < 0.05$. *: significant differences within a group; #: significant differences between SARS-CoV-2-infected and mock-infected groups. **C** Immunoreactivity of SARS-CoV-2 Spike and Nucleocapsid proteins in the lung. **D** Fluorescent in situ RNA hybridization (RNAscope staining) revealed viral Nucleocapsid, Spike, and ORF1ab mRNA in the lung of infected mice and not in mock-infected mice. **E** Iba1 immunoreactivity in the lung of infected K18-hACE2 mice compared with mock-infected mice. Images are representative of $n=5$ per group. Scale bars: 50 μm (**C**, **E**) and 100 μm in **D**

Statistical analysis

Statistical analysis was performed using Prism 10.2.3 (GraphPad Software). For weight loss quantification, a one-way ANOVA based on a mixed-effects model followed by two-stage step-up method of Benjamini, Krieger, and Yekutieli's multiple comparison test (false discovery rate (FDR) < 0.05) was performed for comparison within each group, and a two-way ANOVA followed by Sidak's multiple comparisons test was performed for comparison between mock-infected and SARS-CoV-2-infected groups. In the TG and brainstem, a Shapiro-Wilk normality test was performed for each data set. For unpaired comparison of gene read count, ATF3 and Iba1 staining, between not-infected and SARS-CoV-2-infected groups, a Mann-Whitney test was performed. Each data point represents a single sample. Statistical significance was defined as $p < 0.05$. The specific tests used in each experiment, p -values and p -adjusted are stated in the figure legends when necessary.

Results

Intranasal SARS-CoV-2-infection increased weight loss in K18h-ACE2 transgenic mice

K18-hACE2 mice are a valuable animal model for studying the pathological basis of COVID-19 [18–20]. In this study, we inoculated K18-hACE2 mice intranasally with 2.4×10^4 PFU of SARS-CoV-2, while the control group received a mock treatment (HNE buffer), that were followed for body weight loss for 6 days (Fig. 1A). K18-hACE2 transgenic mice were highly susceptible to SARS-CoV-2 infection, with all mice rapidly losing weight (Fig. 1B). In addition, SARS-CoV-2-infected mice developed signs of clinical manifestations such as ruffled fur, lethargy, swollen face (edema), hunched posture, and orbital tightening. Mock-infected K18-hACE2 transgenic mice remained healthy, maintained their weight, and all survived until 6 days post-injection (DPI).

Regarding the histopathological findings in the lungs, immunofluorescence and in situ hybridization revealed the detection of SARS-CoV-2 N and S proteins and SARS-CoV-2 mRNA (N, S, and ORF1) in SARS-CoV-2-infected mice (Fig. 1C–D) compared to the mock-infected group, in which no protein signal nor staining with multiple RNAscope probes was found (Fig. 1C–D). Additionally, qualitative observation revealed more Iba1-positive cells (macrophages/monocytes), showing


an inflammation in the lung from SARS-CoV-2-infected mice compared to mock-infected animals (Fig. 1E). Next, our explorations focused on two main structures known to participate in orofacial pain, the TG and spinal trigeminal nucleus of the brainstem.

Expression of SARS-CoV-2 entry-related proteins and viral N and S proteins in the TG and brainstem

The orofacial pain symptoms such as migraine, headache and eye pain, reported in patients with COVID-19 may be associated with the invasion of the TG and brainstem by SARS-CoV-2 [1, 21]. Considering that ACE2, NRP-1, and TMPRSS2 have been identified as host entry receptors for SARS-CoV-2 entry [5, 6, 22] (Fig. 2A), we investigated their expression in the TG and brainstem by using a bulk RNA-seq analysis at 6 DPI. The three host entry receptors are expressed in the TG and brainstem from both SARS-CoV-2-infected and mock-infected mice (Fig. 2B). Whereas *Ace2* and *Tmprss2* expressions are almost similar in both tissues (around 10–30 normalized read counts (nrc) as determined by DSEQ2), a higher expression was found for NRP1 in the TG (1000 nrc) compared to the brainstem (around 150–200 nrc). However, the SARS-CoV-2 infection did not change the expression of the three host entry receptors in both tissues.

Next, the quantification of SARS-CoV-2 N and S expression in the TG and brainstem from infected K18-hACE2 transgenic mice revealed that both were detected and more expressed in the two structures compared to mock-mice. We noted a differential expression of S and N genes between tissues, with higher levels observed in the brainstem (10^5 and 10^6 nrc for S and N, respectively) compared to the TG (10^2 and 10^3 nrc for S and N, respectively) (Fig. 2B). Altogether these data confirm that following intranasal inoculation, the virus spreads to both the peripheral nervous system (PNS; TG) and the central nervous system (CNS; brainstem), with a higher viral load detected in the brainstem compared to the TG.

The genome of SARS-CoV-2 contains several genes including ORF1ab, S (encoding the structural spike glycoprotein), ORF3a (ORF3a protein), E (structural envelope protein), M (structural membrane glycoprotein), ORF6 (ORF6 protein), ORF7a (ORF7a protein), ORF7b (ORF7b protein), ORF8 (ORF8 protein), N (structural nucleocapsid phosphoprotein), and ORF10 (ORF10 protein). ORF1ab encodes 16 non-structural proteins. All



(See figure on previous page.)

Fig. 2 Expression of viral host entry receptors and SARS-CoV-2 genes in the TG and brainstem from SARS-CoV-2-infected mice. **A** Entry receptors (ACE2, NRP1, and TMPRSS2.4) are crucial to allow SARS-CoV-2 uptake by host cells [5, 6]. **B** RNA copy numbers of host entry receptors were determined in the TG and brainstem. **C** The viral RNA copy numbers were determined in the TG and brainstem. Each data point within a group represents a mouse. For TG samples, $n = 3$ mock-infected mice and $n = 6$ SARS-CoV-2-infected mice. For brainstem samples, $n = 3$ mock-infected mice and $n = 7$ SARS-CoV-2-infected mice. Results are expressed as the mean $\pm$ SEM. padj of significance in TG and brainstem were extracted from bulk RNAseq database (* padj < 0.05; ** padj < 0.01; *** padj < 0.001 ****; padj < 0.0001)

of them were found increased in the TG and brainstem from SARS-CoV-2-infected mice compared with mock-infected animals (Fig. 2C).

SARS-CoV-2 proteins detection in nociceptive neurons and nerve fibers in the TG from SARS-CoV-2-infected K18-hACE2 mice

Having detected the virus in the TG using RNA-seq techniques, we aimed to visualize SARS-CoV-2 infection using complementary methods. To this end, we used immunofluorescence, in situ hybridization, and scRNA-seq analysis to characterize the cellular and phenotypic distribution of the viral S and N proteins within the TG (Fig. 3A). Neither N nor S viral proteins were detected in mock-infected K18-hACE2 mice (data not shown). Immunohistochemistry analysis confirmed the presence of N protein in trigeminal neurons of the V1, V2 and V3 branches (Fig. 3B–C). Higher magnification revealed different levels of infection in trigeminal neurons. Some neurons exhibited strong, homogeneous N immunoreactivity, whereas other positive neurons exhibited weaker, punctate staining (supplementary Fig. 1).

In addition, N protein was detected in nerve fibers (Fig. 3C, supplementary Fig. 1) in infected K18-hACE2 mice.

To further confirm SARS-CoV-2 infection in nociceptive trigeminal neurons, we performed double in situ hybridization using the highly sensitive and specific RNAscopeTM-based FISH assay. We found that SARS-CoV-2 S mRNA was expressed in nociceptive neurons expressing the transient *Trpv1* gene (Fig. 3D). Furthermore, SARS-CoV-2 N protein was also found colocalizing in nociceptive neurons containing CGRP in K18-hACE2 infected mice (Fig. 3E). The detection of viral S and N proteins in nociceptors is consistent with scRNA-seq data from mouse TG cells [16], which identified that a subset of *Trpv1*- and *Calca*-expressing trigeminal neurons co-expressed *Nrp1* in 16.30% and 31.96% of cases, respectively (Fig. 3F). This co-expression could provide insight into the susceptibility of this specific subpopulation of nociceptive neurons to SARS-CoV-2 infection.

SARS-CoV-2 infection triggers inflammation and neuronal damage in the TG

The presence of SARS-CoV-2 in the TG led us to decipher transcriptome-wide modulations in this structure triggered by the virus. We performed bulk RNA-seq

analysis at 6 DPI to identify the differentially expressed (DE) genes in the TG. Our data showed that 63 genes were significantly regulated (padj < 0.05): 13 genes were upregulated and 50 downregulated (Fig. 4A, C). We performed a pathway enrichment analysis using GeneOntology database on the differentially regulated gene sets (Supplementary Fig. 2). Up-regulated genes are predominantly associated with immune and inflammatory responses, antimicrobial responses, stress signaling, and neuronal apoptosis, consistent with an inflammatory response to infection. In contrast, the down-regulated genes are enriched for distinct pathways related to extracellular matrix organization, metabolic and hormonal regulation, and neuronal maintenance/function. The data are consistent with immune response activation induced by infection accompanied by decrease in metabolic and neuronal functions in the TG.

As a measure of systemic inflammation, we determined chemokine levels in the TG and found that *Ccl2* and *Cxcl10* were significantly increased when compared to mock-infected K18-hACE2 transgenic mice (Fig. 4B–D). The gene of serum amyloid-A (SAA), a marker of inflammation promoting the synthesis of pro-IL-1 β , was also found upregulated in infected mice (Fig. 4B–D). Moreover, our data analysis suggests that lipid metabolism is perturbed in TG after SARS-CoV-2 in association with the inflammatory response. Among the lipid regulatory genes, *Perilipin 4* (*Plin4*) gene encoding a coating protein and regulator of lipid droplets (LDs), was strongly upregulated (Fig. 4B–D).

We next assessed inflammatory responses and neuronal injury in the TG through Iba1 and ATF3 immunostaining, respectively (Fig. 4E–F). Quantitative analysis revealed that SARS-CoV-2-infected K18-hACE2 mice showed a higher number of ATF3-positive cells in the V1, V2 and V3 branches of the TG (Fig. 4E), which correlates with a higher *Atf3* gene expression in TG from SARS-CoV-2-infected K18-hACE2 mice (Fig. 4B, D). In addition, quantitative analysis in V1, V2 and V3 branches revealed higher Iba1 immunoreactivity in the SARS-CoV-2-infected mice compared to control mock-mice (Fig. 4F). Iba1 positive cells displayed enlarged and amoeboid morphological features indicative of macrophage activation and inflammation state. This anatomical feature corroborates with RNA-seq data, showing higher *Ccl2* and *Cxcl10* expression attesting of the trigeminal inflammatory response following viral infection.




Fig. 3 (See legend on next page.)

(See figure on previous page.)

Fig. 3 Cellular distribution of S and N viral proteins in the TG. **A** K18-hACE2 transgenic mice were mock-infected or infected with 2.4×10^4 PFU of SARS-CoV-2. IHC, FISH, and RNA-seq analysis for Spike and Nucleocapsid proteins, CGRP, Calca, Trpv1, and Nrp1 viral host entry receptor were performed on the TG. **B** Confocal image mosaic showing Nucleocapsid protein immunolabeling (red) in a section of the entire TG including the V1, V2 and V3 branches, from a SARS-CoV-2-infected mouse. Scale bar: 500 μ m. **C** Confocal images of double immunolabeling for Nucleocapsid (red) and the neuronal marker β -Tubulin-III (green) in the V1, V2, and V3 branches of the TG from SARS-CoV-2-infected mice. Scale bar: 50 μ m. **D** RNAscope™-based FISH assay labeling viral Spike mRNA (red) and Trpv1 mRNA (green) in SARS-CoV-2 mice. Arrowheads indicate localization of viral Spike protein in nociceptive neurons. Scale bar: 50 μ m. **E** Confocal images of Nucleocapsid protein (red) and CGRP (green) in TG of SARS-CoV-2 mice. Arrows indicate CGRP infected neurons. Scale bar: 50 μ m. **F** scRNA-seq TG cell subpopulation extracted from database analysis [16]. Quantification of *Trpv1/Nrp1* co-expression and *Calca/Nrp1* co-expression extracted from scRNA-seq database

SARS-CoV-2 protein detection in the trigeminal brainstem of infected K18 hACE2 mice

The expression of *Ace2*, *Tmprss2*, and *Nrp1* in the brainstem makes it a prime target for SARS-CoV-2 infection, as shown by our data confirming the presence of SARS-CoV-2 N and S proteins in this brain structure following intranasal administration of SARS-CoV-2 in K18-hACE2 mice (Fig. 2B).

To further assess the cellular phenotype of the infected cells in the brainstem, sections from K18-hACE2 SARS-CoV-2 brainstems were immunostained for N protein together with NeuN, glial fibrillary acidic protein (GFAP), and Iba1, markers for neurons, astrocytes, and microglia, respectively. N protein was exclusively detected in neurons (Fig. 5B), but not in astrocytes (Fig. 5C) or microglial cells (Fig. 5D), suggesting that glial cells are not permissive to infection by SARS-CoV-2 in our experimental conditions. Right panels represent confocal 3D images to better illustrate the different cell populations in the brainstem. In addition, microglial activation occurred in the brainstem of SARS-CoV-2-infected mice, as shown by an activated phenotype characterized by amoeboid morphology and thorny ramifications, along with frequent microglial nodules (Fig. 5D-E). Additional evidence of increased neuroinflammation was found through GFAP immunodetection, which revealed astrocytic hypertrophy extension and thickening of cellular processes (Fig. 5C) when compared to mock-infected mice (not shown).

Infected SARS-CoV-2 neurons are surrounded by CGRP nociceptive fibers in the trigeminal brainstem

A large body of evidence indicates that CGRP, which is released by the trigeminal system, plays a crucial role in the pathophysiology of trigeminal pain such as migraine [2]. We thus explored the distribution of CGRP nociceptive nerve fibers and SARS-CoV-2-infected neurons positive for Nucleocapsid in the trigeminal brainstem in mice (Fig. 6A). A closer analysis showed that N positive neurons were mainly found in the spinal trigeminal nucleus (Sp5C) and C1 segment of the spinal cord (Fig. 6B-C), both regions containing nociceptive neurons [23]. Dense CGRP immunoreactivity was detected in nerve fibers and was restricted within the nociceptive superficial laminae I-II of the caudal part of the Sp5C (Fig. 6B) as expected.

Confocal 3D imaging revealed spatial proximity between CGRP-positive nerve fibers and N positive neurons within laminae I-II (Fig. 6C, Supplementary Video 1).

Transcriptomic analyses identify a robust chemokine and cytokine storm, cell death, neuronal damage, and pain signatures in the brainstem after SARS-CoV-2 infection

To decipher transcriptomic changes induced by viral infection, we performed RNA sequencing analysis on SARS-CoV-2-infected mice brainstem (Fig. 7A).

Bulk RNA-seq analysis done on the brainstem showed that 2609 genes were significantly regulated ($\text{padj} < 0.05$), 1944 genes were upregulated and 665 downregulated (Fig. 7B).

SARS-CoV-2-infected K18-hACE2 transgenic mice exhibit a pronounced cytokine and chemokine storm in the brainstem, with more than 50 genes associated with these pathways showing increased expression (Fig. 7C). Fifty-eight genes were significantly increased in the brainstem relative to mock-infected K18-hACE2 transgenic mice, as previously described in severe COVID-19 patients [24]. Given the implication of the NLRP3 (NOD-, LRR- and pyrin domain-containing protein 3) inflammasome in the pathobiology of migraine [25], we examined whether inflammasome stimulation is induced or dysregulated in SARS-CoV-2-infected mice. We showed that the top genes involved in the activation of NLRP3 inflammasome (*Casp11*, *Casp1*, *Nlrp3*, *Gsdmd*, *Il-1b*, and *Il-18*) were also upregulated in SARS-CoV-2-infected mice. In addition, genes of cell death markers and neuronal damage (*Atf3* and *Lox*) were also increased in SARS-CoV-2 mice. To determine whether a lipid mediator of inflammation signature was found in the brainstem of SARS-CoV-2-infected mice, the prostaglandin gene family was analyzed. The levels of stearoyl-phospholipase A2 genes (*Pla2g4a*, *Pla2g4c*) and prostaglandin synthase genes (*Ptgs2*) were found increased (Fig. 7C). Interestingly, *P2ry12* gene was found decreased in SARS-CoV-2-infected mice, as reported in human medulla from COVID-19 patients [24]. Additionally, genes involved in pain modulation were found increased: *Gfra1*, encodes a co-receptor for glial cell line-derived neurotrophic factor; *Slc17a6* encodes VGLUT2 (Vesicular Glutamate Transporter 2); *Ntrk1* (Neurotrophic receptor tyrosine kinase




Fig. 4 (See legend on next page.)

(See figure on previous page.)

Fig. 4 SARS-CoV-2 triggered inflammation in the TG of infected mice. **A** K18-hACE2 transgenic mice were mock-infected or infected with 2.4×10^4 PFU of SARS-CoV-2. Bulk RNA-seq analysis and IHC for cell death marker *Atf3* and macrophage marker *Iba1* were performed on TG. **B** Volcano plot showing DE genes in SARS-CoV-2-infected versus mock-infected mice. Genes with significant up-regulation or down-regulation are shown in red (p-value and $\log_2FC$), blue (p-value only), and green ($\log_2FC$ only). All other non-significant genes are shown in gray. **C** Gene expression data obtained from mock-infected ($n=3$) and SARS-CoV-2-infected ($n=5$) mice. Heatmap showing normalized expression of differentially expressed (DE) genes of interest ($\text{padj} < 0.05$) between mock-infected and SARS-CoV-2-infected mice. **D** Quantification of five up-regulated genes in TGs. Results are expressed as the mean $\pm$ SEM (mock-infected mice: $n=3$, SARS-CoV-2-infected mice: $n=5$). **E** Epifluorescence images of immunolabeling of *Atf3* (E) in the TG of Mock- and SARS-CoV-2-infected mice. White arrowheads indicate *Atf3*-positive cells. Quantification of *Atf3*-positive cells in V1, V2 and V3 branches. Results are expressed as mean $\pm$ SEM (mock-infected mice: $n=3$, SARS-CoV-2-infected mice: $n=6$). * $p < 0.05$ compared to mock-infected mice. **F** Epifluorescence images of immunolabeling of *Iba1* (F) in the TG of mock- and SARS-CoV-2-infected mice. White arrows indicate *Iba1*-positive cells. Quantification of the *Iba1*-positive area fraction in the V1, V2 and V3 branches. Results are expressed as mean $\pm$ SEM (mock-infected mice: $n=4$, SARS-CoV-2-infected mice: $n=7$). * $p < 0.05$, ** $p < 0.01$ compared to mock-infected mice. **E-F** Scale bar: 50 μm

1) encodes *TrkA*, the high-affinity receptor for nerve growth factor; *Ptgs2* (Prostaglandin-endoperoxide synthase 2) encodes COX-2, an enzyme that catalyzes the formation of prostaglandins key mediators of inflammation-induced pain; *Tacr1* (Tachykinin receptor 1) encodes the NK1 receptor (neurokinin-1), the main receptor for substance P; *Pla2g4a* (Phospholipase A2 group IVA / cPLA2 α) and *Pla2g4c* encode cytosolic phospholipase A2 alpha and gamma, respectively, which contribute to inflammatory pain, hyperalgesia, as well as chronic pain maintenance *via* central mechanisms.

Genes related to neuronal activation (*Jun*, *Fos*, *Fosb*) were also highly expressed in the brainstem from infected SARS-CoV-2 compared to mock-infected mice. As seen in the TG, part of the peripheral nervous system, we also demonstrated the higher expression of the COVID-19 severity markers *Cxcl10*, *Ccl2*, *Atf3*, *Plin4*, and *Saa3*.

Saa3, Cxcl10, Plin4, Ccl2, and Atf3 genes as biomarkers of the severity of the virus infection in TG and brainstem

The data found above, together with a recent meta-analysis, indicates an association between cytokine/chemokine levels and COVID-19 severity, with severe cases showing significantly elevated levels of cytokines (TNF- α , IL-5, IL-6, IL-10) and chemokines (CCL2, CXCL10) [26]. Consistently, we further found that expression of the viral Spike gene increased in parallel with the expression of *Saa3*, *Cxcl10*, *Plin4*, *Ccl2*, and *Atf3* in both the TG and brainstem (Fig. 8A-B), suggesting that these five genes constitute good markers of COVID-19 disease.

Gene association networks for the TG and brainstem

To investigate the biological functions linked to SARS-CoV-2 infection in the TG and brainstem, we performed functional enrichment analysis. Specifically, we used Over-Representation Analysis on the differentially expressed genes in the TG (Fig. 9A) and brainstem (Fig. 9B-C). The analysis was limited to GO Biological Process terms, with enrichment tested using Benjamini-Hochberg correction and a significance cutoff of $p < 0.05$.

For the TG analysis, we generated a cnetplot based on a selection of GO pathways associated with lipid,

inflammation, chemotaxis, and axon injury (Fig. 9A). *Ccl2*, as mentioned before, emerges as a major hub gene, involved in chemokine signaling, TNF response, humoral immune response, and chemotaxis. Similarly, *Adipoq* is associated with TNF response, lipid metabolism, and oxidative stress; *Fabp4* links lipid metabolism with TNF signaling; and *Mmp2* is involved in chemotaxis, axon injury, and oxidative stress.

For the brainstem, the top 10 GO terms were determined and clearly indicate overrepresentation of more than 100 genes involved in inflammatory pathways and response to virus (Fig. 9B).

To clarify the role and interaction of these enriched genes, we generated a cnetplot for the top 3 terms: regulation of immune effector processes, regulation of innate immune response, and response to virus (Fig. 9C). This analysis clearly shows a coordinated upregulation of chemokines, cytokines, and their receptors, providing compelling evidence of the cytokine storm triggered by SARS-CoV-2 infection. In addition, SARS-CoV-2 infection was accompanied by increased expression of several Toll-like receptor (TLR) genes (Fig. 9C).

Discussion

The trigeminal nerve, the fifth cranial nerve, plays a critical role in transmitting sensory information from the face to the brain. Damage or dysregulation to this nerve is associated with conditions such as trigeminal neuralgia, headache, migraine, clinical symptoms frequently reported in patients with coronavirus disease 2019 (COVID-19) [27, 28]. Despite these observations, the underlying mechanisms linking SARS-CoV-2 infection to trigeminal dysfunction were not investigated. In this study we used a mouse model intranasally inoculated with SARS-CoV-2 to study cellular and molecular alterations in the trigeminal sensory pathway, specifically focusing on the TG and associated brainstem regions.

SARS-CoV-2 transport from the nasal cavity to the trigeminal ganglion and brainstem

Recent studies have suggested that the trigeminal system, including the TG and trigeminal brainstem, could serve




Fig. 5 (See legend on next page.)

(See figure on previous page.)

Fig. 5 Detection of viral infection and inflammation in the spinal trigeminal nucleus of the brainstem of SARS-CoV-2-infected mice. **A** K18-hACE2 transgenic mice were mock-infected or infected with 2.4×10^4 PFU of SARS-CoV-2. Immunoreactivity of Nucleocapsid, GFAP, and Iba1 in the brainstem of mock-infected and/or SARS-CoV-2-infected mice. **B–D** Confocal images of double-immunolabeling of Nucleocapsid (red) with NeuN (neuronal cells; green; **B**), GFAP (astrocytic cells; green; **C**) or Iba1 (microglial cells; green; **D**) in the brainstem of SARS-CoV-2-infected mice. Scale bar: 50 μ m. 3D reconstruction (right panels) provided insight into the spatial relationship and distribution pattern of Nucleocapsid (red) and NeuN (green) (**B**), Nucleocapsid (red) and GFAP (green) (**C**), and Nucleocapsid (red) and Iba1 (green) (**D**). White labeling corresponds to DAPI staining. Scale bar: 15 μ m. **E** Immunoreactivity of Iba1 in SARS-CoV-2-infected mice compared to mock-infected mice presenting an activated phenotype feature of inflammation. Scale bar: 200 μ m. Right panels show magnification of the plain line inset. Scale bar: 100 μ m

as a key pathway for SARS-CoV-2 neurotropic infection, contributing to symptoms such as anosmia and migraine [29]. Our data provide the first evidence that all known viral entry sites -ACE2, NRP1, and the protease TMPRSS2- are expressed in both the TG and brainstem in K18-hACE2 transgenic mice. This is consistent with previous clinical observation reporting ACE2 and TMPRSS2 expression in the TG of COVID-19 patients [21]. This suggests that SARS-CoV-2 may travel from the nasal cavity to the brainstem via the trigeminal nerve. Further supporting this hypothesis, we observed expression of SARS-CoV-2 viral S protein binding sites in axons within the TG, indicating neuronal trafficking along trigeminal nerve fibers.

A previous study has revealed SARS-CoV-2 S immunostaining in the TG from intranasally challenged AC70 hACE2 (hACE2) transgenic mice at an earlier timepoint (3 DPI), suggesting that viral infection of the trigeminal nerve occurred nearly simultaneously with the olfactory nerve [30]. Our data represent the first in vivo demonstration of transport of SARS-CoV-2 along the trigeminal nerve in vivo, a crucial finding in understanding the virus's neuroinvasive potential. Previous studies have reported anterograde and retrograde transport of the virus within trigeminal nerve afferents using in vitro approaches [31]. Our in vivo data provide direct evidence that SARS-CoV-2 N protein is present in axons stained with β -Tubulin-III antibody, as well as in neuronal soma and neurites within the V1, V2 and V3 branches of the TG, with no labeling observed in mock-infected mice. These findings confirm that nerve terminals in orofacial regions, including those of the trigeminal nerve, serve as entry points for SARS-CoV-2, enabling viral invasion into the brainstem. Moreover, SARS-CoV-2 neuroinvasion may not be limited to the trigeminal nerve. Other potential entry points for the virus include the olfactory neuroepithelium, the eyes, and the mucosal surfaces of the oral and nasal cavities. These sites of entry are directly connected to the CNS, providing additional pathways for viral trafficking to the brain. Thus, direct neuronal invasion via retrograde and anterograde transports, as well as potential hematogenous routes, are likely mechanisms for SARS-CoV-2 entry into the CNS.

SARS-CoV-2 viral protein detected in TRPV1 and CGRP trigeminal nociceptors

One of the main questions was to determine the possible detection of SARS-CoV-2 in primary sensory neurons, and especially in nociceptors (CGRP⁺, TRPV1⁺), known to play a key role in trigeminal pain and sensory disturbance. NRP1 has recently been suggested as an alternative way to enter the neurons [32, 33]. scRNA-seq analysis revealed that this host entry receptors is expressed in CGRP and TRPV1 sensory neurons. Such co-expression is in accordance with a study reporting the key role of NRP1 in modulating pain pathways in a rat model of spinal nerve injury [34]. Here, by combining in situ hybridization and immunohistological analysis, we provide the demonstration of the detection of S and N proteins in CGRP and TRPV1 nociceptive trigeminal neurons. A study [35] reports that vagal C-fibers innervating the lung, including both TRPV1⁺ and TRPV1⁻ populations, fire action potentials in response to S protein. While this has not yet been directly demonstrated for trigeminal neurons, these data suggest that trigeminal C-fibers could potentially exhibit similar responsiveness.

Considering that TRPV1 antagonists have not demonstrated efficacy in migraine clinical trials (reviewed in [36]) and that there is currently no strong clinical evidence supporting a direct causal role for TRPV1 in migraine pathophysiology, our data on the cellular and molecular expression of TRPV1 should not be interpreted as direct evidence of migraine-relevant mechanisms in the context of COVID-19.

In addition, immunohistochemistry analyses revealed increased inflammation, as evidenced by elevated Iba1 staining) as well as marker of neuronal damage (ATF3) in the V1, V2 and V3 branches of the TG from infected mice. These alterations suggest a contribution to sensory neuron sensitization and pain manifestation in the context of COVID-19.

Trigeminal neuroinflammation as a driver of pain related to COVID-19

The primary sensory nociceptive neurons, expressing TRPV1 and CGRP, can also be overactivated by locally released inflammatory mediators such as cytokines and




Fig. 6 SARS-CoV-2-infected neurons and CGRP-containing fibers in the caudal part of the spinal trigeminal nucleus of the brainstem of SARS-CoV-2-infected mice. **A** K18-hACE2 transgenic mice were infected with 2.4×10^4 PFU of SARS-CoV-2 and immunolabelings for Nucleocapsid protein and CGRP were performed in the brainstem. **B** Confocal images of double-immunolabeling of CGRP (red) with Nucleocapsid (green) in the caudal part of the spinal trigeminal nucleus (Sp5C). In the left panel, a schematic drawing from Paxinos and Franklin atlas illustrates the layers of the Sp5C (I, II, III-IV). Scale bar: 100 μ m. **C** 3D reconstructions provide insight into spatial relationship and distribution pattern of infected neurons (Nucleocapsid, green) and CGRP nerve fibers (red) in the superficial (I and II) layers of the Sp5C. Scale bar: 15 μ m

chemokines, leading to a sustained pain state [37–39]. Activation of nociceptive neurons has been widely acknowledged as an important player in acute and chronic pain, including migraine (reviewed in [40]).

Central pain sensitization involves multiple molecular players and mechanisms that enhance excitatory signaling and promote neuroinflammation. The NK1 receptor, encoded by *Tacr1*, plays a crucial role in mediating neurogenic inflammation and facilitating synaptic transmission within the brainstem, both of which are key contributors to central sensitization [41]. Additionally,

the phospholipases A2, encoded by *Pla2g4a* and *Pla2g4c* genes, are involved in the synthesis of pro-inflammatory lipid mediators, such as prostaglandins, which further amplify pain signaling in central pathways [42]. A critical aspect of pain transmission is the involvement of VGLUT2-positive neurons, which are essential for the release of glutamate from excitatory neurons. These neurons are crucial in the amplification of nociceptive signals in brain regions that process pain [43]. Here, we reported an increased expression of *Slc17a6*, the gene encoding VGLUT2, in the brainstem of infected mice. This finding




Fig. 7 (See legend on next page.)

(See figure on previous page.)

Fig. 7 SARS-CoV-2 triggered inflammation in brainstem of infected mice. **A** K18-hACE2 transgenic mice were mock-infected or infected with 2.4×10^4 PFU of SARS-CoV-2. Bulk RNA-seq analysis was performed on the brainstem. **B** Volcano plot showing differentially expressed (DE) genes in SARS-CoV-2-infected versus mock-infected mice. Genes with significant up-regulation or down-regulation are shown in red (p -value and Log_2FC), blue (p -value only) and green (Log_2FC only). All other non-significant genes are shown in gray. **C** Gene expression data obtained from mock-infected ($n=3$) and SARS-CoV-2-infected ($n=7$) mice. Heatmap showing normalized expression of DE genes of interest ($\text{padj} < 0.05$) between mock-infected and SARS-CoV-2-infected mice. **D** Quantification of five up-regulated genes in brainstems. Results are expressed as the mean $\pm$ SEM (mock-infected mice: $n=3$, SARS-CoV-2-infected mice: $n=7$)

suggests that heightened glutamate release in the central nervous system may contribute to the intensification of trigeminal pain. Taken together, the upregulation of genes implicated in pain modulation, particularly those controlling neuronal excitability, synaptic plasticity, and neuroinflammatory signaling, likely underlies the maintenance and exacerbation of trigeminal pain observed in COVID-19 patients.

A cytokine storm has been described during the pathogenesis of severe COVID-19 disease in patients (as reviewed in [44]). Our RNAseq data clearly confirm that SARS-CoV-2 infection in K18-hACE2 transgenic mice induces a robust inflammatory response in the brainstem, characterized by elevated expression of cytokine (e.g., *Tnf*, *Il1*, *Il2*, *Il6*, *Il18*, *Ifng*) and chemokine (e.g., *Ccl2/Ccr2*, *Ccl5/Ccr5*, *Cxcl10*) indicative of the activation of glial and microglial cells.

This is further supported by morphological changes observed in astrocytes and microglia within the brainstem. Both astrocytes and microglial cells are known to play key roles in neuroinflammation and orofacial pain condition [45]. Our data are consistent with previous clinical observations reporting altered morphology and reduced branching of the GFAP-immunostained astrocytes in brains of COVID-19 patients [46].

In addition, our findings suggest that neurons are the primary target of SARS-CoV-2 viral tropism in the brainstem, rather than astrocytes or microglia. Finally, we found SARS-CoV-2-infected neurons in the trigeminal brainstem being closely surrounded by CGRP-positive nociceptive fibers. This anatomical feature suggests a potential association between infected neurons and CGRP nociceptive fibers, without implying direct interaction; given that activation of CGRP fibers in the brainstem plays a key role in trigeminal pain [2], our data suggest that this association may be relevant to the emergence of pain-related symptoms in COVID-19.

The contribution of neurogenic inflammation to migraine pathophysiology remains an area of ongoing debate. Although experimental studies have demonstrated trigeminovascular activation and neuropeptide-mediated signaling, clinical evidence for a sustained or classical inflammatory process in migraine has been inconsistent (for reviews [47–49]). In addition, differences in inflammatory profiles across migraine clinical states may have significant implications for understanding disease mechanisms, progression, and potential

therapeutic interventions [49]. Thus, neurogenic inflammation is one of several proposed mechanisms contributing to migraine-like pathology rather than an established or exclusive driver. In this context, our findings support a potent central neuroinflammatory signaling in SARS-CoV-2-infected mice, without implying that this mechanism is necessary or sufficient for migraine pathology.

SARS-CoV-2 and severity biomarkers

Long-term cytokine activity results in excessive levels of cytokines which are known as a “cytokine storm”. CXCL10 has been identified as a very important factor in modulating the course and the intensity of inflammation caused by SARS-CoV-2 in humans and animal models [50–52]. CXCL10 activates its receptor, CXCR3, which is mainly expressed on macrophages, T lymphocytes, dendritic cells, natural killer cells, and B cells [53]. Moreover, CXCL10 has been proposed as a biomarker associated with disease severity and mortality risk in COVID-19 patients [54]. Consistent with these findings, our data demonstrate that this chemokine is also upregulated in the TG and brainstem, suggesting that it may serve as a potential biomarker of SARS-CoV-2-induced neuroinflammation. Our data also revealed that CCL2/MCP-1 levels increased with the viral particles number in both the TG and brainstem. Elevated levels of *Cxcl10* and *Ccl2* have been reported in migraine patients [55, 56] and are known to play a key role in pain [57] and neuroinflammation, reinforcing the link between migraine associated with COVID-19 and these chemokines.

Proinflammatory cytokines promote the overexpression of an acute phase apolipoprotein called serum amyloid-A (SAA) [58]. SAA is well-established as a marker of inflammation, promoting the synthesis of pro-IL-1 β , activating the NLRP3 inflammasome, and inducing the production of various cytokines and chemokines. More than 83% of the COVID-19 patients who had abnormally elevated serum SAA levels [59–61] and serum SAA concentrations were significantly and positively associated with higher COVID-19 severity and mortality [62]. It was proposed that sustained SAA expression marks poor prognosis with low survival rate in COVID-19 patients [63–65]. Here, we provide the first evidence that Saa3 is both expressed in TG and brainstem and is also correlated with viral load, confirming that SAA could serve as a biomarker for COVID-19 progression.




Fig. 8 (See legend on next page.)

(See figure on previous page.)

Fig. 8 Expression of *Saa3*, *Cxcl10*, *Plin4*, *Ccl2*, and *Atf3* genes in the TG and brainstem relative to Spike expression. **A** K18-hACE2 transgenic mice were mock-infected or infected with 2.4×10^4 PFU of SARS-CoV-2. Correlation between the Spike expression and *Saa3*, *Cxcl10*, *Plin4*, *Ccl2*, and *Atf3* gene expression in the TG and brainstem. **B** Spike expression in the TG and brainstem relative to *Saa3*, *Cxcl10*, *Plin4*, *Ccl2*, and *Atf3* gene expression levels (TG: $n = 3$ for mock (blue dot) and $n = 5$ for SARS-CoV-2 (red dot) groups, brainstem: $n = 3$ for mock (blue dot) and $n = 7$ for SARS-CoV-2 (red dot) groups). Each dot represents an animal

Virus replication and assembly depend on the hijacking of host cell lipid metabolism, as many viruses, including SARS-CoV-2, actively reprogram lipid synthesis, trafficking, and storage to support viral replication and repackaging [66]. This metabolic renewing often results in the accumulation of intracellular LDs, which serve not only as lipid reservoirs but also as platforms for viral replication. Accordingly, LDs have emerged as key organelles at the intersection of energy metabolism, cellular signaling, and infection-associated stress responses [67]. LD dynamics are mainly regulated by members of the perilipin family (Plin1-5), which control LDs formation, stability, and turnover, and thereby influence lipid homeostasis and ferroptosis susceptibility. Growing evidence indicates that excessive intracellular LDs deposition contributes to lipotoxicity and precedes neurodegeneration [68]. Among perilipins, Plin4 interacts with the LD membrane to form a protective barrier that limits uncontrolled lipolysis. In neurons, Plin4 is required to promote the functional coupling between LDs and mitochondria, enabling β -oxidation during inflammatory and oxidative stress conditions [69, 70]. Disruption of the Plin4-LD-mitophagy axis has been implicated in neuronal degeneration, highlighting Plin4-associated LDs as both a potential biomarker and therapeutic target in Parkinson's disease [70]. In our mouse model of SARS-CoV-2, a higher expression of *Plin4* in the TG and brainstem was found in combination with increased levels of neuronal injury and inflammatory genes. These findings suggest that *Plin4* may represent a COVID-19 severity-associated gene, potentially linking viral lipid hijacking to neuronal vulnerability. While lipid accumulation has been reported in the lungs of COVID-19 patients [71], the specific role and mechanistic contribution of Plin4-regulated LDs to SARS-CoV-2 neuropathogenesis remain poorly understood and warrant further investigation.

Collectively, our findings shed light on the mechanisms potentially driving trigeminal pain manifestations, including headache and migraine, following SARS-CoV-2 infection.

Limitations

This study has several limitations. The first one is related to the experimental model we used in this study. In K18-hACE2 mice, the human ACE2 transgene is driven by the keratin 18 promoter, resulting in non-physiological levels

and spatial patterns of ACE2 expression, including in CNS and PNS tissues. Consequently, this model is prone to severe CNS infection that may not fully recapitulate the extent, distribution, or mechanisms of SARS-CoV-2 neuropathology observed in humans. Therefore, caution is warranted when extrapolating findings related to CNS infection and associated clinical manifestations, such as migraine or other pain-related symptoms, to human disease. Nevertheless, despite these limitations, hACE2 transgenic mouse models, including K18-hACE2 and AC70 mice, remain valuable experimental tools for investigating SARS-CoV-2 neuroinvasion and neuropathogenic mechanisms.

Limitations of this study also include the use of a single post-infection timepoint, which primarily reflects molecular mechanisms associated with acute SARS-CoV-2 infection and does not capture potential post-acute or long-term changes. Inclusion of earlier time points would provide complementary information into the initial stages of TG infection and represent an important direction for future studies.

The absence of functional validation assays, such as calcium imaging, electrophysiology, or pain-related behavioral testing, limits direct association of the observed molecular alterations to sensory neuron function. Future studies including longitudinal analyses and functional assays will be important to validate the physiological relevance of these findings.

RNA-seq analysis was performed on whole TG, providing a global transcriptomic profile of the tissue. Consequently, the molecular alterations reported in this study cannot be specifically attributed to the migraine-relevant V1 branch, as this approach does not allow discrimination among the V1, V2, and V3 branches. Furthermore, while quantitative analyses were performed when technically feasible, some immunohistochemical staining are described qualitatively, which represents a limitation of the present study.

A limitation of the present study is that only male mice were used. Migraine is more prevalent in females, and accumulating evidence indicates that sex-dependent differences exist in CGRP signaling (reviewed in [72, 73]), neuroinflammation and pain processing (see reviews [74, 75]). The literature comparing the effects of CGRP in male and female rodents demonstrate broadly similar pronociceptive behaviors in both sexes, with consistently

Category Groups

- Cellular stress response
- Chemotaxis
- Chemokine signaling
- Lipid & cholesterol homeostasis
- Immunity
- TNF response

D

regulation of immune effector process
 regulation of innate immune response
 response to virus
 leukocyte cell-cell adhesion
 positive regulation of response to biotic stimulus
 positive regulation of cell activation
 positive regulation of innate immune response
 regulation of leukocyte cell-cell adhesion
 leukocyte proliferation
 defense response to virus

p.adjust Count

2.197588e-58 ○ 128
 1.393040e-47 ○ 136
 2.786080e-47 ○ 151
 4.179120e-47 ○ 143
 5.572161e-47 ○ 166
 ○ 168

GeneRatio

FoldChange Size

7.5 ● 151
 5.0 ● 166
 2.5 ● 168
 0.0

Ccl6 Il12rb1

regulation of immune effector process

regulation of innate immune response

response to virus

Fig. 9 (See legend on next page.)

(See figure on previous page.)

Fig. 9 Gene network maps for the trigeminal ganglion and brainstem. Nodes represent genes (labeled by their log fold change) and enriched GO terms, illustrating the functional relationships between genes and biological processes. **A** Trigeminal ganglion. Cnetplot displaying a selection of GO pathways and related genes. The size of the dots related to a specific GO pathway represents the number of connections in the list. The color of the dots represents the Log2 Fold Change. Genes in common with brainstem samples are highlighted in gray. **B** Dotplot of top 10 GO terms for the brainstem in order of gene ratio. The gene ratio represents the proportion of differentially expressed genes that are associated with a given enriched term. The size of the dots represents the number of genes in the significant DE gene list associated with the GO terms, and the color of the dots represents the p-adjusted values. **C** Gene-concept network for the brainstem. The top 3 terms were listed, and related genes were connected. The connection of genes to the corresponding GO is marked with a special color. The size of the node related to a specific GO term represents the number of DE genes. A selection of genes from the heatmap presented in Fig. 7 and the TLR family gene have been highlighted

greater magnitude and sensitivity observed in females. These preclinical data align with clinical observations in humans, supporting a more prominent role for CGRP signaling in female migraine patients [76, 77]. Therefore, the cellular and molecular changes described here in male mice may differ in females. Future studies incorporating female animals will be important to fully evaluate the translational relevance of these findings and to determine whether sex-specific mechanisms contribute to the observed effects induced by SARS-CoV-2.

Abbreviations

ACE2	Angiotensin-converting enzyme 2
CGRP	Calcitonin gene-related peptide
CNS	Central nervous system
COVID-19	Coronavirus Disease 2019
GFAP	Glial fibrillary acidic protein
Iba1	Ionized calcium-binding adaptor molecule 1
IHC	Immunohistochemistry
LD	Lipid droplet
N	Nucleocapsid
NRP1	Neuropilin-1
PNS	Peripheral nervous system
S	Spike
TG	Trigeminal ganglion
TMPPRSS2	Transmembrane protease, serine 2
TRPV1	Transient receptor potential vanilloid 1

Supplementary Information

The online version contains supplementary material available at <https://doi.org/10.1186/s12974-026-03722-5>.

Supplementary Material 1: Supplementary Fig. 1. Representative image showing nucleocapsid immunoreactivity in neurons and nerve fibers of the TG from an infected mouse. Arrowheads indicate highly infected neurons; asterisks mark less infected neurons, characterized by punctuate staining; arrows denote nucleocapsid-stained nerve fibers. Scale bar: 100 μ m.

Supplementary Material 2: Supplementary Fig. 2. Enriched Gene Ontology Terms in Up- and Down-Regulated Genes in TG. Functional enrichment analysis of Gene Ontology (GO) terms was performed using enrichGO to identify biological processes significantly associated with up- (A) and down- (B) regulated genes in TG. Results are visualized as dotplots, with each dot representing an enriched GO term. The x-axis indicates the *GeneRatio*, calculated as the proportion of input genes annotated to a GO term, while the y-axis lists the enriched GO terms. The top 40 GO terms are displayed for both up- and down-regulated gene sets. Dot size corresponds to the number of genes mapped to each term, and dot color represents the statistical significance of enrichment (adjusted p-value), with red indicating higher significance and blue lower significance.

Supplementary Material 3: Supplementary video 1. 3D reconstruction of CGRP positive nerve fibers and SARS-CoV-2-infected neurons. Note the close proximity between infected neurons and nociceptive fibers in the brainstem of SARS-CoV-2-infected mice.

Acknowledgements

We thank the Paris Vision Institute core facilities (the animal care staff; zoo technicians, imaging platform, and the cellular and tissue phenotyping platform). We would like to thank Dr. Noémie Bonneau for technical help. The Paris Vision Institute is affiliated to DIM C-BRAINS, funded by the Conseil Régional d'Ile-de-France.

Authors' contributions

J.H. conducted histology, RNAscope FISH, acquired data, analyzed data, and contributed to figures and text to the manuscript. I.M, S.M, A-G.M virus preparation. L. Bi infection and monitoring of mice, tissue harvesting. C.E infection and monitoring of mice, tissue harvesting. S.M performed mouse intranasal injections. E.R performed confocal images and contributed to RNA extraction, and preparation of the samples for RNA-seq explorations. S.F performed 3D confocal images. E.G analyzed RNA-seq data and contributed to figures. F.B provided input on RNA-seq analysis. F.C design and supervision of infection protocol of mice. L.Bo. design and supervision of infection protocol of mice, obtaining funding and contributed to a figure. W.R, C.B, and S.M.P provided scientific input and advice on manuscript. X.G analyzed the RNA-seq samples, contributed to figures, provided scientific input and advice on manuscript. L.B.R and A.R.L.G designed and supervised the experiments, prepared the figure, obtained funding and wrote the manuscript.

Funding

This work was supported by the Centre National de la Recherche Scientifique (CNRS), the Institut National de la Santé et de la Recherche Médicale (INSERM), IHU FOReSIGHT grant (ANR-18-IAHU-01), Fondation Dalloz - Institut de France, China Scholarship Council thesis fellowship (J.H) and Agence Nationale de la Recherche (ANR, grant to L.Bo, COVID-NeuroResp; ANR-RA-COVID-19-V3).

Data availability

Data generated during this study and referenced in this manuscript are available from the corresponding author upon reasonable request.

Declarations

Ethics approval and consent to participate

'Not applicable' for that section.

Consent for publication

'Not applicable' for that section.

Competing interests

The authors declare no competing interests.

Author details

¹Sorbonne Université, INSERM, CNRS, Institut de la Vision, IHU FOReSIGHT, Paris F-75012, France

²Sorbonne Université, INSERM, UMR51158 Neurophysiologie Respiratoire Expérimentale et Clinique, Paris F-75005, France

³Sorbonne Université, UMS 28, INSERM, Faculté de Médecine, Paris F-75013, France

⁴Iasi University of Life Sciences (IULS), Iasi, Roumanie

⁵Sorbonne Université, INSERM, Institut Pierre Louis d'Epidémiologie et de Santé Publique, (IPLESP), Paris F-75013, France

⁶CHNO des Quinze-Vingts, INSERM-DGOS CIC 1423, Paris F-75012, France

⁷Université Versailles-Saint-Quentin-en-Yvelines (UVSQ), Versailles F-78000, France

⁸AP-HP, Hôpital Pitié Salpêtrière, Service de Virologie, Paris F-75013, France

⁹Université Paris Cité, Paris F-75006, France

Received: 26 November 2025 / Accepted: 2 February 2026

Published online: 16 February 2026

References

- Caronna E, Ballve A, Llauro A, Gallardo VJ, Ariton DM, Lallana S, Lopez Maza S, Olive Gadea M, Quibus L, Restrepo JL, et al. Headache: A striking prodromal and persistent symptom, predictive of COVID-19 clinical evolution. *Cephalalgia*. 2020;40:1410–21.
- Edvinsson L, Ho TW. CGRP receptor antagonism and migraine. *Neurotherapeutics*. 2010;7:164–75.
- Haanes KA, Edvinsson L. Pathophysiological mechanisms in migraine and the identification of new therapeutic targets. *CNS Drugs*. 2019;33:525–37.
- Garate G, Toriello M, Gonzalez-Quintanilla V, Perez-Pereda S, Madera J, Pascual M, Olmos JM, Pascual J. Serum alpha-CGRP levels are increased in COVID-19 patients with headache indicating an activation of the trigeminal system. *BMC Neurol*. 2023;23:109.
- Iwata-Yoshikawa N, Kakizaki M, Shiwa-Sudo N, Okura T, Tahara M, Fukushi S, Maeda K, Kawase M, Asanuma H, Tomita Y, et al. Essential role of TMPRSS2 in SARS-CoV-2 infection in murine airways. *Nat Commun*. 2022;13:6100.
- Cantuti-Castelvetri L, Ojha R, Pedro LD, Djannatian M, Franz J, Kuivanen S, van der Meer F, Kallio K, Kaya T, Anastasina M, et al. Neuropilin-1 facilitates SARS-CoV-2 cell entry and infectivity. *Science*. 2020;370:856–60.
- Wang W, Chen J, Yu X, Lan HY. Signaling mechanisms of SARS-CoV-2 nucleocapsid protein in viral infection, cell death and inflammation. *Int J Biol Sci*. 2022;18:4704–13.
- Singh M, Bansal V, Feschotte C. A Single-Cell RNA expression map of human coronavirus entry factors. *Cell Rep*. 2020;32:108175.
- Edvinsson JCA, Vigano A, Alekseeva A, Alieva E, Arruda R, De Luca C, D'Ettore N, Frattale I, Kurnukhina M, Macerola N, et al. The fifth cranial nerve in headaches. *J Headache Pain*. 2020;21:65.
- Moreau GB, Burgess SL, Sturek JM, Donlan AN, Petri WA, Mann BJ. Evaluation of K18-hACE2 mice as a model of SARS-CoV-2 infection. *Am J Trop Med Hyg*. 2020;103:1215–9.
- Jiang RD, Liu MQ, Chen Y, Shan C, Zhou YW, Shen XR, Li Q, Zhang L, Zhu Y, Si HR, et al. Pathogenesis of SARS-CoV-2 in Transgenic mice expressing human Angiotensin-Converting enzyme 2. *Cell*. 2020;182:50–8. e58.
- Bao L, Deng W, Huang B, Gao H, Liu J, Ren L, Wei Q, Yu P, Xu Y, Qi F, et al. The pathogenicity of SARS-CoV-2 in hACE2 Transgenic mice. *Nature*. 2020;583:830–3.
- Tyagi K, Rai P, Gautam A, Kaur H, Kapoor S, Sutttee A, Jaiswal PK, Sharma A, Singh G, Barnwal RP. Neurological manifestations of SARS-CoV-2: complexity, mechanism and associated disorders. *Eur J Med Res*. 2023;28:307.
- Meinhardt J, Radke J, Dittmayer C, Franz J, Thomas C, Mothes R, Laue M, Schneider J, Brunink S, Greuel S, et al. Olfactory transmucosal SARS-CoV-2 invasion as a Port of central nervous system entry in individuals with COVID-19. *Nat Neurosci*. 2021;24:168–75.
- Jeong GU, Kwon HJ, Ng WH, Liu X, Moon HW, Yoon GY, Shin HJ, Lee IC, Ling ZL, Spiteri AG, et al. Ocular tropism of SARS-CoV-2 in animal models with retinal inflammation via neuronal invasion following intranasal inoculation. *Nat Commun*. 2022;13:7675.
- Yang L, Xu M, Bhuiyan SA, Li J, Zhao J, Cohrs RJ, Susterich JT, Signorelli S, Green U, Stone JR, et al. Human and mouse trigeminal ganglia cell atlas implicates multiple cell types in migraine. *Neuron*. 2022;110:1806–e18211808.
- Preibisch S, Saalfeld S, Tomancak P. Globally optimal Stitching of tiled 3D microscopic image acquisitions. *Bioinformatics*. 2009;25:1463–5.
- McCray PB Jr, Pewe L, Wohlford-Lenane C, Hickey M, Manzel L, Shi L, Netland J, Jia HP, Halabi C, Sigmund CD, et al. Lethal infection of K18-hACE2 mice infected with severe acute respiratory syndrome coronavirus. *J Virol*. 2007;81:813–21.
- Clever S, Volz A. Mouse models in COVID-19 research: analyzing the adaptive immune response. *Med Microbiol Immunol*. 2023;212:165–83.
- Seehusen F, Clark JJ, Sharma P, Bentley EG, Kirby A, Subramaniam K, et al. Neuroinvasion and neurotropism by SARS-CoV-2 variants in the K18-hACE2 mouse. *Viruses*. 2022;14(5):1020.
- Park GC, Bang SY, Lee HW, Choi KU, Kim JM, Shin SC, Cheon YI, Sung ES, Lee M, Lee JC, et al. ACE2 and TMPRSS2 immunolocalization and oral manifestations of COVID-19. *Oral Dis*. 2022;28(Suppl 2):2456–64.
- Jackson CB, Farzan M, Chen B, Choe H. Mechanisms of SARS-CoV-2 entry into cells. *Nat Rev Mol Cell Biol*. 2022;23:3–20.
- Pradier B, McCormick SJ, Tsuda AC, Chen RW, Atkinson AL, Westrick MR, Buckholtz CL, Kauer JA. Properties of neurons in the superficial laminae of trigeminal nucleus caudalis. *Physiol Rep*. 2019;7:e14112.
- Fekete R, Simats A, Biro E, Posfai B, Cserep C, Schwarcz AD, Szabadits E, Kornyei Z, Toth K, Ficho E, et al. Microglia dysfunction, neurovascular inflammation and focal neuropathologies are linked to IL-1- and IL-6-related systemic inflammation in COVID-19. *Nat Neurosci*. 2025;28:558–76.
- He W, Long T, Pan Q, Zhang S, Zhang Y, Zhang D, Qin G, Chen L, Zhou J. Microglial NLRP3 inflammasome activation mediates IL-1beta release and contributes to central sensitization in a recurrent nitroglycerin-induced migraine model. *J Neuroinflammation*. 2019;16:78.
- Zhang Z, Ai G, Chen L, Liu S, Gong C, Zhu X, Zhang C, Qin H, Hu J, Huang J. Associations of immunological features with COVID-19 severity: a systematic review and meta-analysis. *BMC Infect Dis*. 2021;21:738.
- Souza DD, Shivde S, Awatere P, Avati A, John SK, Badachi S, Nadig R, Sarma G, Mathew T. Headaches associated with acute SARS-CoV-2 infection: A prospective cross-sectional study. *SAGE Open Med*. 2021;9:20503121211050227.
- Togha M, Hashemi SM, Yamani N, Martami F, Salami Z. A review on headaches due to COVID-19 infection. *Front Neurol*. 2022;13:942956.
- Messlinger K, Neuhuber W, May A. Activation of the trigeminal system as a likely target of SARS-CoV-2 May contribute to anosmia in COVID-19. *Cephalalgia*. 2022;42:176–80.
- Hsu JC, Saenkhom-Huntsinger P, Huang P, Octaviani CP, Drelich AK, Peng BH, Tseng CK. Characterizing neuroinvasion and neuropathology of SARS-CoV-2 by using AC70 human ACE2 Transgenic mice. *Front Microbiol*. 2024;15:1455462.
- de Melo GD, Perraud V, Alvarez F, Vieites-Prado A, Kim S, Kergoat L, Coleon A, Trueb BS, Tichit M, Piazza A, et al. Neuroinvasion and anosmia are independent phenomena upon infection with SARS-CoV-2 and its variants. *Nat Commun*. 2023;14:4485.
- Hopkins C, Lechien JR, Saussez S. More than ACE2? NRP1 May play a central role in the underlying pathophysiological mechanism of olfactory dysfunction in COVID-19 and its association with enhanced survival. *Med Hypotheses*. 2021;146:110406.
- Joyce JD, Moore GA, Goswami P, Harrell TL, Taylor TM, Hawks SA, et al. SARS-CoV-2 rapidly infects peripheral sensory and autonomic Neurons, contributing to central nervous system neuroinvasion before viremia. *Int J Mol Sci*. 2024;25(15):8245.
- Gomez K, Duran P, Tonello R, Allen HN, Boinon L, Calderon-Rivera A, Loya-Lopez S, Nelson TS, Ran D, Moutal A, et al. Neuropilin-1 is essential for vascular endothelial growth factor A-mediated increase of sensory neuron activity and development of pain-like behaviors. *Pain*. 2023;164:2696–710.
- Kim JS, Ru F, Meeker S, Undem BJ. Direct activation of airway sensory C-fibers by SARS-CoV-2 S1 Spike protein. *Physiol Rep*. 2023;11:e15900.
- Ashraf U, Goadsby PJ. Migraine: advances in treatment. *Trends Mol Med*. 2025;S1471-4914(25):00205–9.
- Melik Parsadaniantz S, Rivat C, Rostene W, Reaux-Le Goazigo A. Opioid and chemokine receptor crosstalk: a promising target for pain therapy? *Nat Rev Neurosci*. 2015;16:69–78.
- Grace PM, Hutchinson MR, Maier SF, Watkins LR. Pathological pain and the neuroimmune interface. *Nat Rev Immunol*. 2014;14:217–31.
- Ji RR, Chamesian A, Zhang YQ. Pain regulation by non-neuronal cells and inflammation. *Science*. 2016;354:572–7.
- Ho TW, Edvinsson L, Goadsby PJ. CGRP and its receptors provide new insights into migraine pathophysiology. *Nat Rev Neurol*. 2010;6:573–82.
- Alpay B, Christensen RH, Al-Khazali HM, Ashina M, Ashina H. Substance P and the trigeminovascular system: from preclinical mechanisms to human headache induction. *Cephalalgia*. 2025;45:3331024251355944.
- Svensson CI, Yaksh TL. The spinal phospholipase-cyclooxygenase-prostanoid cascade in nociceptive processing. *Annu Rev Pharmacol Toxicol*. 2002;42:553–83.
- Lagerstrom MC, Rogoz K, Abrahamsen B, Persson E, Reinius B, Nordenan-kar K, Olund C, Smith C, Mendez JA, Chen ZF, et al. VGLUT2-dependent sensory neurons in the TRPV1 population regulate pain and itch. *Neuron*. 2010;68:529–42.
- Coperchini F, Chiovato L, Croce L, Magri F, Rotondi M. The cytokine storm in COVID-19: an overview of the involvement of the chemokine/chemokine-receptor system. *Cytokine Growth Factor Rev*. 2020;53:25–32.
- Ye Y, Salvo E, Romero-Reyes M, Akerman S, Shimizu E, Kobayashi Y, et al. Glia and orofacial pain: progress and future directions. *Int J Mol Sci*. 2021;22(10):5345.

46. Rosu GC, Mateescu VO, Simionescu A, Istrate-Ofiteru AM, Curca GC, Pirici I, Mogoanta L, Mindrila I, Kumar-Singh S, Hostiuc S, Pirici D. Subtle vascular and astrocytic changes in the brain of coronavirus disease 2019 (COVID-19) patients. *Eur J Neurol*. 2022;29:3676–92.
47. Williamson DJ, Hargreaves RJ. Neurogenic inflammation in the context of migraine. *Microsc Res Tech*. 2001;53:167–78.
48. Musubire AK, Cheema S, Ray JC, Hutton EJ, Matharu M. Cytokines in primary headache disorders: a systematic review and meta-analysis. *J Headache Pain*. 2023;24:36.
49. Stuchfield-Denby E, Pereira B, Bouvier D, Dallel R, Moisset X. Distinct inflammatory profiles across migraine states: a systematic review and meta-analysis. *J Headache Pain*. 2025;26:219.
50. Gudowska-Sawczuk M, Mroczko B. What is currently known about the role of CXCL10 in SARS-CoV-2 infection? *Int J Mol Sci*. 2022;23(7):3673.
51. Zhang N, Zhao YD, Wang XM. CXCL10 an important chemokine associated with cytokine storm in COVID-19 infected patients. *Eur Rev Med Pharmacol Sci*. 2020;24:7497–505.
52. Mulchandani R, Lyngdoh T, Kakkar AK. Deciphering the COVID-19 cytokine storm: systematic review and meta-analysis. *Eur J Clin Invest*. 2021;51:e13429.
53. Oladunni FS, Park JG, Pino PA, Gonzalez O, Akhter A, Allue-Guardia A, Olmo-Fontanez A, Gautam S, Garcia-Vilanova A, Ye C, et al. Lethality of SARS-CoV-2 infection in K18 human angiotensin-converting enzyme 2 Transgenic mice. *Nat Commun*. 2020;11:6122.
54. Chen Y, Wang J, Liu C, Su L, Zhang D, Fan J, Yang Y, Xiao M, Xie J, Xu Y, et al. IP-10 and MCP-1 as biomarkers associated with disease severity of COVID-19. *Mol Med*. 2020;26:97.
55. Ran C, Olofsgard FJ, Wellfelt K, Steinberg A, Belin AC. Elevated cytokine levels in the central nervous system of cluster headache patients in bout and in remission. *J Headache Pain*. 2024;25:121.
56. Ryu S, Liu X, Guo T, Guo Z, Zhang J, Cao YQ. Peripheral CCL2-CCR2 signalling contributes to chronic headache-related sensitization. *Brain*. 2023;146:4274–91.
57. Aloyouny AY, Bepari A, Rahman I. Evaluating the role of CXCR3 in pain modulation: A literature review. *J Pain Res*. 2020;13:1987–2001.
58. De Buck M, Gouwy M, Wang JM, Van Snick J, Proost P, Struyf S, Van Damme J. The cytokine-serum amyloid A-chemokine network. *Cytokine Growth Factor Rev*. 2016;30:55–69.
59. Liu J, Tu C, Zhu M, Wang J, Yang C, Liu W, Xiong B. The clinical course and prognostic factors of severe COVID-19 in Wuhan, china: A retrospective case-control study. *Med (Baltim)*. 2021;100:e23996.
60. Wang R, Pan M, Zhang X, Han M, Fan X, Zhao F, Miao M, Xu J, Guan M, Deng X, et al. Epidemiological and clinical features of 125 hospitalized patients with COVID-19 in Fuyang, Anhui, China. *Int J Infect Dis*. 2020;95:421–8.
61. Zhang JJ, Dong X, Cao YY, Yuan YD, Yang YB, Yan YQ, Akdis CA, Gao YD. Clinical characteristics of 140 patients infected with SARS-CoV-2 in Wuhan, China. *Allergy*. 2020;75:1730–41.
62. Almusalami EM, Lockett A, Ferro A, Posner J. Serum amyloid A-A potential therapeutic target for hyper-inflammatory syndrome associated with COVID-19. *Front Med (Lausanne)*. 2023;10:1135695.
63. Yu Y, Liu T, Shao L, Li X, He CK, Jamal M, Luo Y, Wang Y, Liu Y, Shang Y, et al. Novel biomarkers for the prediction of COVID-19 progression a retrospective, multi-center cohort study. *Virulence*. 2020;11:1569–81.
64. Pieri M, Ciotti M, Nuccetelli M, Perrone MA, Calio MT, Lia MS, Minieri M, Bernardini S. Serum amyloid A protein as a useful biomarker to predict COVID-19 patients severity and prognosis. *Int Immunopharmacol*. 2021;95:107512.
65. Zinellu A, Paliogiannis P, Caru C, Mangoni AA. Serum amyloid A concentrations, COVID-19 severity and mortality: an updated systematic review and meta-analysis. *Int J Infect Dis*. 2021;105:668–74.
66. Mesquita I, Estaquier J. Viral manipulation of the host metabolic network. *Exp Suppl*. 2018;109:377–401.
67. Herker E, Vieyres G, Beller M, Krahmer N, Bohnert M. Lipid droplet contact sites in health and disease. *Trends Cell Biol*. 2021;31:345–58.
68. Stiles CD. The biological role of oncogenes—insights from platelet-derived growth factor: Rhoads memorial award lecture. *Cancer Res*. 1985;45:5215–8.
69. Copic A, Antoine-Bally S, Gimenez-Andres M, La Torre Garay C, Antonny B, Manni MM, Pagnotta S, Guihot J, Jackson CL. A giant amphipathic helix from a perilipin that is adapted for coating lipid droplets. *Nat Commun*. 2018;9:1332.
70. Han X, Zhu J, Zhang X, Song Q, Ding J, Lu M, Sun S, Hu G. Plin4-Dependent lipid droplets hamper neuronal mitophagy in the MPTP/p-Induced mouse model of parkinson's disease. *Front Neurosci*. 2018;12:397.
71. Grootemaat AE, van der Niet S, Scholl ER, Roos E, Schurink B, Bugiani M, Miller SE, Larsen P, Pankras J, Reits EA, van der Wel NN. Lipid and nucleocapsid N-Protein accumulation in COVID-19 patient lung and infected cells. *Microbiol Spectr*. 2022;10:e0127121.
72. Avona A, Burgos-Vega C, Burton MD, Akopian AN, Price TJ, Dussor G. Dural calcitonin Gene-Related peptide produces Female-Specific responses in rodent migraine models. *J Neurosci*. 2019;39:4323–31.
73. Lewter LA, Arnold RL, Narosov NB, Dussor G, Kolber BJ. Sex differences in the effects of calcitonin gene-related peptide signaling on migraine-like behavior in animal models: a narrative review. *Front Neurol*. 2025;16:1603758.
74. Mogil JS. Qualitative sex differences in pain processing: emerging evidence of a biased literature. *Nat Rev Neurosci*. 2020;21:353–65.
75. Mogil JS, Parisien M, Esfahani SJ, Diatchenko L. Sex differences in mechanisms of pain hypersensitivity. *Neurosci Biobehav Rev*. 2024;163:105749.
76. Krause DN, Warfvinge K, Haanes KA, Edvinsson L. Hormonal influences in migraine - interactions of oestrogen, Oxytocin and CGRP. *Nat Rev Neurol*. 2021;17:621–33.
77. Labastida-Ramirez A, Rubio-Beltran E, Villalon CM, MaassenVanDenBrink A. Gender aspects of CGRP in migraine. *Cephalalgia*. 2019;39:435–44.

Publisher's note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.